ESC Premium Access

Discussant review: Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial

Topic: Lipids (Epidemiology and Prevention)

Presentation

About the speaker

Professor John Chapman

Sorbonne University, Paris (France)
15 presentations
0 follower

12 more presentations in this session

Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial

Speaker: Professor M. Landray (Oxford, GB)

Thumbnail

Panel discussion.

Thumbnail

Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study

Speaker: Professor H. Itoh (Tokyo, JP)

Thumbnail

Discussant review: Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study

Speaker: Professor E. Prescott (Copenhagen, DK)

Thumbnail

Panel discussion.

Thumbnail

Access the full session

Hot Line: Late-Breaking Clinical Trials 4

Speakers: Professor J. Chapman, Professor M. Landray, Professor H. Itoh, Professor E. Prescott
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk